Cannenta announces first patients in human trials of their unique pro-angiogenic wound treatment.

Cannenta has reached a major milestone with the commencement of its first human trial for its’ CANN001 (hydrogel dressings with 2dDR), designed to promote angiogenesis and accelerate would healing.

Patients with diabetic foot ulcers are now being treated in a Phase 1 clinical trial conducted by the Multidisciplinary Diabetes Foot Ulcer (MDFU) service at Fiona Stanley Hospital with Prof. Laurens Manning as the principal investigator. The study is being coordinated by the University of Western Australia.

This exciting milestone for Cannenta coincides with new investment in the company to support ongoing commercialisation activities.

Preclinical studies have shown that ‘2dDR’ is a powerful stimulant of angiogenesis (blood vessel formation) – a crucial factor in healing of poorly vascularised wounds such as diabetic foot ulcers and other chronic wounds.

The 2dDR technology is suitable for incorporating into a range of standard dressing materials, making it available for treatment of a variety of wound indications at an early stage in treatment to help prevent delayed wound healing and associated complications.

Cannenta is actively working to commercialise the technology in advanced and developing countries through strategic partnerships with manufacturers and distributors.

For more information contact enquiries@cannenta.com